Cytokinetics to Participate in September Investor Conferences
Cytokinetics will host September 2026 fireside chats at multiple New York healthcare investor conferences with live and archived webcasts.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cytokinetics (CYTK) will participate in several healthcare investor conferences in September 2026, each featuring a management fireside chat.
Events include the Citi 2026 BioPharma Back to School Conference on Sept. 9 at 3:00 PM ET, the Cantor Global Healthcare Conference 2026 on Sept. 10 at 11:30 AM ET, the Morgan Stanley 24th Annual Global Healthcare Conference on Sept. 14 at 7:45 AM ET, and the Bernstein 3rd Annual Healthcare Forum on Sept. 23 at 8:50 AM ET, all in New York, NY. Live webcasts and 90-day replays will be available via the Investors & Media section of the Cytokinetics website.
Details
News Market Reaction – CYTK
On Sep 3, the first trading day after this news, CYTK closed 2.81% above the previous close. Relative volume reached 1.5x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 3 session.
Key Figures
- Citi conference date
- September 9, 2026 at 3:00 PM Eastern Time
- Citi 2026 BioPharma Back to School Conference
- Cantor conference date
- September 10, 2026 at 11:30 AM Eastern Time
- Cantor Global Healthcare Conference 2026
- Morgan Stanley conference date
- September 14, 2026 at 7:45 AM Eastern Time
- Morgan Stanley 24th Annual Global Healthcare Conference
- Bernstein conference date
- September 23, 2026 at 8:50 AM Eastern Time
- Bernstein 3rd Annual Healthcare Forum
- Morgan Stanley conference edition
- 24th annual
- Morgan Stanley Global Healthcare Conference
- Bernstein forum edition
- 3rd annual
- Bernstein Healthcare Forum
- Webcast replay period
- 90 days
- Following conclusion of each event
Historical Context
-
ACACIA-HCM met dual primary endpoints despite reported safety concerns
-
Company announced upcoming ESC Congress presentations and investor event
-
Company granted options and RSUs to twelve newly hired employees
-
Quarterly loss widened while the company reported revenue and cash
-
MHRA authorized MYQORZO and NICE issued positive treatment guidance
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September:
- Citi 2026 BioPharma Back to School Conference: Fireside chat on Wednesday, September 9, 2026 at 3:00 PM Eastern Time in New York, NY.
- Cantor Global Healthcare Conference 2026: Fireside chat on Thursday, September 10, 2026 at 11:30 AM Eastern Time in New York, NY.
- Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat on Monday, September 14, 2026 at 7:45 AM Eastern Time in New York, NY.
- Bernstein 3rd Annual Healthcare Forum: Fireside chat on Wednesday, September 23, 2026 at 8:50 AM Eastern Time in New York, NY.
Interested parties may access the live webcasts of the fireside chats by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the approved in the U.S., China, European Union and United Kingdom for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union and the United Kingdom.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which September 2026 investor conferences will Cytokinetics (CYTK) attend?
Cytokinetics will participate in four events: the Citi 2026 BioPharma Back to School Conference, the Cantor Global Healthcare Conference 2026, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum, all held in New York, NY.
When are Cytokinetics (CYTK) fireside chats scheduled during the September 2026 conferences?
The fireside chats are scheduled for Sept. 9, 2026 at 3:00 PM ET (Citi), Sept. 10 at 11:30 AM ET (Cantor), Sept. 14 at 7:45 AM ET (Morgan Stanley), and Sept. 23 at 8:50 AM ET (Bernstein).
How can investors access the Cytokinetics (CYTK) September 2026 conference webcasts?
Interested parties may access the live webcasts of Cytokinetics’ September 2026 fireside chats by visiting the Investors & Media section of the company’s website at http://www.cytokinetics.com.
How long will replays of the Cytokinetics (CYTK) September 2026 fireside chats be available?
Webcast replays of the Cytokinetics September 2026 fireside chats will be archived on the company’s website for 90 days following the conclusion of each event.